TLR2 and coronary artery disorder: The 5‐LO/LTB4 pathway plays a significant role in modulating the TLR pathway, and both 5‐LO and FLAP inhibition resulted in abrogated TLR‐2‐, ‐3‐, and ‐4‐mediated phagocytosis (Ebert et al. 2020); of these, TLR‐2 and ‐4 were found to be elevated in EAT tissue from CAD patients (Vianello et al. 2016).